
LSTA Stock Forecast & Price Target
LSTA Analyst Ratings
Bulls say
Lisata Therapeutics Inc. is experiencing promising developments in its investigational product, certepetide, which has demonstrated a positive trend in overall survival, as indicated by preliminary data from ASCO GI. The company has reported notable results from Cohort A, highlighting four complete responses in the certepetide group, and further data from Cohort B suggests that a second dose may enhance progression-free survival (PFS) and overall response rate (ORR) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). As a clinical-stage pharmaceutical company focused on delivering innovative therapies for solid tumors, Lisata's advancements in certepetide position it favorably within the pharmaceutical landscape, contributing to a positive outlook for its stock.
Bears say
Lisata Therapeutics Inc. faces significant risks that could negatively impact its stock, primarily due to the potential for failed or inconclusive clinical trials related to its investigational product, certepetide. Additionally, the company's ability to secure sufficient funding to advance its drug development is a critical concern that raises uncertainty about future growth prospects. Overall, the combination of these clinical and financial challenges contributes to a negative outlook on the company’s stock performance.
This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LSTA Analyst Forecast & Price Prediction
Start investing in LSTA
Order type
Buy in
Order amount
Est. shares
0 shares